Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
PMC
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005.
Eur. J. Cancer 43, 974-978 (2007)
Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded.The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Imatinib; Cardiotoxicity; GIST
ISSN (print) / ISBN
0959-8049
e-ISSN
1879-0852
Zeitschrift
European Journal of Cancer
Quellenangaben
Band: 43,
Heft: 6,
Seiten: 974-978
Verlag
Elsevier
Begutachtungsstatus
Peer reviewed
Institut(e)
CCG Tumor Therapy with Hyperthermia (IMI-KTH)